miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway

Zhang,Zhiqiang; Zhang,Jinku; Li,Jinmei; Geng,Huijuan; Zhou,Bingjuan; Zhang,Bingxin; Chen,Hong

doi:10.3892/ol.2020.11440

miR‑320/ELF3 axis inhibits the progression of breast cancer via the PI3K/AKT pathway

Authors:
- Zhiqiang Zhang
- Jinku Zhang
- Jinmei Li
- Huijuan Geng
- Bingjuan Zhou
- Bingxin Zhang
- Hong Chen
View Affiliations

Affiliations: Department of Thoracic Surgery, Baoding First Central Hospital, Baoding, Hebei 071000, P.R. China, Department of Pathology, Baoding First Central Hospital, Baoding, Hebei 071000, P.R. China, Department of Clinical Laboratory, Baoding Infectious Diseases Hospital, Baoding, Hebei 071000, P.R. China
Published online on: March 3, 2020 https://doi.org/10.3892/ol.2020.11440
Pages: 3239-3248
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is increasing evidence demonstrating that disorders affecting microRNAs (miRs) influence tumorigenesis and progression, which results in a poor prognosis in patients with breast cancer (BC). In the present study, the precise molecular mechanism underlying the role of miR‑320 in the progression of BC was investigated. Reverse transcription‑quantitative PCR was conducted to determine mRNA expression, and western blot analysis was used to test protein levels. An MTT assay was conducted to detect cell viability and Transwell assays were used to analyze cell migration and invasion abilities. Furthermore, E74‑like factor 3 (ELF3) protein density was tested via immunohistochemistry. Tumor volume was detected by xenograft tumor formation assay. The current results indicated that miR‑320 expression was downregulated in BC tissues and cells, and was associated with a poor prognosis of patients with BC. Overexpression of miR‑320 inhibited cell proliferation, migration and invasion via inhibition of the epithelial‑mesenchymal transition and the PI3K/AKT signaling pathway in BC cells. Furthermore, it was revealed that the tumor size and weight were smaller in nude mice that had been transfected to overexpress miR‑320. The luciferase reporter assay demonstrated the direct binding of miR‑320 to the 3' untranslated region of ELF3 mRNA, which may further downregulate ELF3. Overall, the present results provided evidence that miR‑320 may be a tumor suppressor in BC, and that the miR‑320/ELF3 axis regulated tumor progression via the PI3K/AKT signaling pathway, which may represent a novel treatment strategy for BC.

View Figures

View References

1	Hong W and Dong E: The past, present and future of breast cancer research in China. Cancer Lett. 351:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ren L, Li Y, Zhao Q, Fan L, Tan B, Zang A and Yang H: miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R. Oncol Lett. 19:1567–1576. 2020.PubMed/NCBI
3	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
4	Zuo TT, Zheng RS, Zeng HM, Zhang SW and Chen WQ: Female breast cancer incidence and mortality in China, 2013. Thorac Cancer. 8:214–218. 2017. View Article : Google Scholar : PubMed/NCBI
5	Dinami R, Buemi V, Sestito R, Zappone A, Ciani Y, Mano M, Petti E, Sacconi A, Blandino G, Giacca M, et al: Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. Oncotarget. 8:95674–95691. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhao J and Jiang GQ: miR-4282 inhibits proliferation, invasion and metastasis of human breast cancer by targeting Myc. Eur Rev Med Pharmacol Sci. 22:8763–8771. 2018.PubMed/NCBI
7	Lieb V, Weigelt K, Scheinost L, Fischer K, Greither T, Marcou M, Theil G, Klocker H, Holzhausen HJ, Lai X, et al: Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients. Oncotarget. 9:10402–10416. 2017.PubMed/NCBI
8	Zhang H and Lu W: LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miR-320. Mol Med Rep. 17:2743–2749. 2018.PubMed/NCBI
9	Bai JW, Wang X, Zhang YF, Yao GD and Liu H: MicroRNA-320 inhibits cell proliferation and invasion in breast cancer cells by targeting SOX4. Oncol Lett. 14:7145–7152. 2017.PubMed/NCBI
10	Oettgen P, Alani RM, Barcinski MA, Brown L, Akbarali Y, Boltax J, Kunsch C, Munger K and Libermann TA: Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol. 17:4419–4433. 1997. View Article : Google Scholar : PubMed/NCBI
11	Neve RM, Parmar H, Amend C, Chen C, Rizzino A and Benz CC: Identification of an epithelial-specific enhancer regulating ESX expression. Gene. 367:118–125. 2006. View Article : Google Scholar : PubMed/NCBI
12	Wang JL, Chen ZF, Chen HM, Wang MY, Kong X, Wang YC, Sun TT, Hong J, Zou W, Xu J and Fang JY: Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death Dis. 5:e12632014. View Article : Google Scholar : PubMed/NCBI
13	Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, et al: ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression. Cancer Res. 73:4533–4547. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J, Ding S and Zhang J: Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 94:98–106. 2018. View Article : Google Scholar : PubMed/NCBI
15	Iwai S, Amekawa S, Yomogida K, Sumi T, Nakazawa M, Yura Y, Nishimune Y and Nozaki M: ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. Oral Dis. 14:144–149. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yeung TL, Leung CS, Wong KK, Gutierrez-Hartmann A, Kwong J, Gershenson DM and Mok SC: ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 8:16951–16963. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ke K and Lou T: MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway. Oncol Lett. 14:5994–6000. 2017.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ke SB, Qiu H, Chen JM, Shi W and Chen YS: MicroRNA-202-5p functions as a tumor suppressor in colorectal carcinoma by directly targeting SMARCC1. Gene. 676:329–335. 2018. View Article : Google Scholar : PubMed/NCBI
20	Quan H, Li B and Yang J: MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling. Biomed Pharmacother. 107:754–762. 2018. View Article : Google Scholar : PubMed/NCBI
21	Duan S, Dong X, Hai J, Jiang J, Wang W, Yang J, Zhang W and Chen C: MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2. Biomed Pharmacother. 107:712–720. 2018. View Article : Google Scholar : PubMed/NCBI
22	Rohini M, Gokulnath M, Miranda PJ and Selvamurugan N: miR-590-3p inhibits proliferation and promotes apoptosis by targeting activating transcription factor 3 in human breast cancer cells. Biochimie. 154:10–18. 2018. View Article : Google Scholar : PubMed/NCBI
23	Yan L, Yu MC, Gao GL, Liang HW, Zhou XY, Zhu ZT, Zhang CY, Wang YB and Chen X: miR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. J Cell Biochem. 119:8773–8783. 2018. View Article : Google Scholar : PubMed/NCBI
24	Li C, Zhang J, Ma Z, Zhang F and Yu W: miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 11:4087–4095. 2018. View Article : Google Scholar : PubMed/NCBI
25	Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D and Schiemann WP: TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 123:150–163. 2013. View Article : Google Scholar : PubMed/NCBI
26	Luo L, Yang R, Zhao S, Chen Y, Hong S, Wang K, Wang T, Cheng J, Zhang T and Chen D: Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1. Acta Biochim Biophys Sin (Shanghai). 50:473–480. 2018. View Article : Google Scholar : PubMed/NCBI
27	Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D and Stratakis CA: Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene. 32:1651–1659. 2013. View Article : Google Scholar : PubMed/NCBI
28	Li T, Ma J, Han X, Jia Y, Yuan H, Shui S and Guo D: MicroRNA-320 enhances radiosensitivity of glioma through down-regulation of sirtuin type 1 by directly targeting forkhead box protein M1. Transl Oncol. 11:205–212. 2018. View Article : Google Scholar : PubMed/NCBI
29	Zhao W, Sun Q, Yu Z, Mao S, Jin Y, Li J, Jiang Z, Zhang Y, Chen M, Chen P, et al: miR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. Gene. 670:31–37. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zheng L, Xu M, Xu J, Wu K, Fang Q, Liang Y, Zhou S, Cen D, Ji L, Han W and Cai X: ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma. Cell Death Dis. 9:3872018. View Article : Google Scholar : PubMed/NCBI
31	Fang J, Ding M, Yang L, Liu LZ and Jiang BH: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 19:2487–2497. 2007. View Article : Google Scholar : PubMed/NCBI
32	Dong Y, Liang G, Yuan B, Yang C, Gao R and Zhou X: MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 36:1477–1486. 2015. View Article : Google Scholar : PubMed/NCBI
33	Qiu N, He YF, Zhang SM, Zhan YT, Han GD, Jiang M, He WX, Zhou J, Liang HL, Ao X, et al: Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway. Cancer Lett. 464:25–36. 2019. View Article : Google Scholar : PubMed/NCBI